The Role of the New Anti-CD20 Monoclonal Antibodies in Active Relapsing – Remitting Multiple Sclerosis Treatment: Efficacy and Safety of ofatumumab

Multiple sclerosis is the most common chronic demyelinating neurodegenerative central nervous system disease among young adults. Considering its extent in a relatively young population, multiple sclerosis determines a significant socioeconomic burden to the society due to the cost of disease modify...

Celý popis

Podrobná bibliografie

Hlavní autoři:	I. Jonušaitė, N. Giedraitienė, G. Kaubrys, R. Kizlaitienė
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Vilnius University Press 2024-03-01
Edice:	Neurologijos seminarai
Témata:	multiple sclerosis economic burden anti-CD20 therapy monoclonal antibodies ofatumumab
On-line přístup:	https://test.zurnalai.vu.lt/neurologijos_seminarai/article/view/34911
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!